The Regulars

Pharmalot Ed Silverman

STAT Plus: AbbVie sues a behind-the-scenes company for exploiting its patient assistance program

Pharmalot Ed Silverman

STAT Plus: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA panel recommends first OTC birth control pill; Senate hearing on insulin costs satisfies no one

Pharmalot Ed Silverman

STAT Plus: FDA panel votes in favor of the first over-the-counter birth control pill

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Gilead wins lawsuit against HHS over HIV pill patents; most Americans say abortion pill should remain on the market

Pharmalot Ed Silverman

STAT Plus: What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history

Pharmalot Ed Silverman

STAT Plus: Gilead defeats federal government in closely watched battle over patents for HIV prevention pills

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA panel to review over-the-counter birth control pill; Alzheimer’s drugs may lead to haves and have-nots

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pfizer and Valneva delay application for Lyme vaccine; Moderna adjusts price for Covid-19 shot

Pharmalot Ed Silverman

STAT Plus: NIH grant recipients often fail to disclose agency support in patent applications

Pharmalot Ed Silverman

STAT Plus: NIH systems for non-human primate research fall short, threatening biomedical research

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA OKs first RSV vaccine for older adults; Lilly Alzheimer’s data puts pressure on Medicare

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Lilly’s Alzheimer’s drug slowed cognitive decline; most EU countries back plan to push production of key drugs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Senate delays PBM-reform bill effective date; Gilead and HHS square off in court over HIV patents

Pharmalot Ed Silverman

STAT Plus: A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial

Pharmalot Ed Silverman

STAT Plus: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: More biotechs are betting on obesity; Pfizer RSV vaccine faces hurdles in low-income countries

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: Amgen ends two lupus programs; Illumina sequencers have security vulnerability

Pharmalot Ed Silverman

STAT Plus: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: Lilly’s Mounjaro helped people lose 15.7% of body weight; Sanofi earnings boosted by Dupixent

Pharmalot Damian Garde

STAT Plus: Pharmalittle: EU unveils sweeping pharma reforms; new eye drug helps Roche beat the street

Pharmalot Damian Garde

STAT Plus: Pharmalittle: Novartis boosts its sales and profit outlook; Biogen trims its drug pipeline

Pharmalot Ed Silverman

STAT Plus: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Weight-loss drug makers lobby Congress for Medicare coverage; Europe braces for new pharma legislation

Pharmalot Ed Silverman and Andrew Joseph

STAT Plus: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings